Shuai Li | Biology and Life Sciences | Innovative Research Award

Published on by Innovation Technologist

Innovative Research Award

Shuai Li
Regeneron, United States
Shuai Li
Affiliation Regeneron
Country United States
Scopus ID 60597499200
Documents 6
Citations 221
h-index 4
Subject Area Biology and Life Sciences
Event Global Innovation Technologist Awards
ORCID 0000-0002-1537-3956

The Innovative Research Award recognizes the scholarly and scientific contributions of Shuai Li, a researcher associated with Regeneron and previously affiliated with Duke University. Li has contributed to interdisciplinary research spanning synthetic biology, metabolic engineering, supramolecular chemistry, and automated bioprocess technologies. The research portfolio demonstrates a combination of experimental innovation, engineering methodology, and translational biological applications within the broader field of biology and life sciences.[1]

Abstract

Shuai Li has developed a multidisciplinary academic profile integrating biological engineering, synthetic biology, supramolecular chemistry, and automation systems for laboratory applications. Published works include contributions to metabolic engineering in Escherichia coli, chiral molecular assemblies, CRISPR-associated biological systems, and open-source laboratory automation. The body of work reflects ongoing efforts to optimize biological production systems, enhance molecular recognition strategies, and improve accessibility to bioprocess instrumentation.[2][3]

Keywords

Synthetic Biology; Metabolic Engineering; Bioprocess Automation; Supramolecular Chemistry; CRISPR Systems; NADPH Flux; Chiroptical Switches; Biological Engineering; Automated Sampling Systems; Life Sciences Research.

Introduction

Contemporary life sciences research increasingly depends upon interdisciplinary approaches that integrate chemistry, engineering, automation, and computationally informed biological experimentation. Shuai Li’s scholarly contributions reflect this evolving research landscape through work involving engineered microbial systems, supramolecular interfaces, and laboratory automation platforms.[4]

Li completed academic training at Shandong University and the Institute of Chemistry of the Chinese Academy of Sciences before continuing research activities at Duke University. These educational and research experiences contributed to a broad methodological background that spans chemical sciences and biotechnology-oriented engineering disciplines.[1]

Research Profile

The Scopus author profile associated with Shuai Li reports 221 citations across multiple indexed documents and an h-index of 4, indicating measurable academic engagement and scholarly visibility within biotechnology and chemistry-related research communities.[1]

Research topics explored by Li include metabolic pathway optimization, enzyme regulation, supramolecular assembly, CRISPR/Cas systems, and automated sampling technologies for bioreactors. Publications demonstrate collaborations across academic laboratories and interdisciplinary scientific environments.[5]

  • Research specialization in synthetic biology and metabolic engineering.
  • Contributions to supramolecular and chiral chemistry methodologies.
  • Development of low-cost automated laboratory technologies.

Research Contributions

Among Li’s notable contributions is the development of the BioSamplr, an open-source automated sampling system designed for bioreactors. The platform aimed to provide a lower-cost alternative for laboratory sampling automation, thereby increasing accessibility for smaller research laboratories and educational institutions.[2]

Li also contributed to research focused on improving NADPH flux and xylitol biosynthesis in engineered E. coli systems through dynamic regulatory control strategies. This work addressed feedback regulation mechanisms and metabolic optimization relevant to industrial biotechnology applications.[3]

Additional studies investigated CRISPR-associated endonuclease complexes and their effects on self-targeting spacer stability. These findings contributed to understanding microbial genome regulation and CRISPR system functionality.[6]

In the field of supramolecular chemistry, Li co-authored studies examining chiroptical switches, chiral metallogels, and self-assembled polydiacetylene systems for enantioselective recognition. These works demonstrated applications of molecular self-assembly and chirality transfer in advanced chemical systems.[7][8]

Publications

  1. BioSamplr: An open source, low cost automated sampling system for bioreactors — HardwareX (2021).
  2. Dynamic control over feedback regulatory mechanisms improves NADPH flux and xylitol biosynthesis in engineered E. coli — Metabolic Engineering (2021).
  3. Escherichia coli Cas1/2 Endonuclease Complex Modifies Self-Targeting CRISPR/Cascade Spacers Reducing Silencing Guide Stability — ACS Synthetic Biology (2020).
  4. Supramolecular chiroptical switches — Chemical Society Reviews (2020).
  5. Self-Assembled Polydiacetylene Vesicle and Helix with Chiral Interface for Visualized Enantioselective Recognition of Sulfinamide — ACS Applied Materials & Interfaces (2017).

Research Impact

The academic impact of Li’s work is reflected through citations, interdisciplinary collaborations, and publication in peer-reviewed journals covering biotechnology, synthetic biology, materials science, and supramolecular chemistry. Research outputs have relevance for both academic investigation and industrial biotechnology applications.[3][7]

The integration of engineering principles with biological systems research has contributed to emerging methodologies in automated experimentation and metabolic pathway optimization. Such interdisciplinary work supports broader scientific efforts aimed at improving efficiency, reproducibility, and accessibility in laboratory research environments.[2]

Award Suitability

Shuai Li’s multidisciplinary research background aligns with the objectives of the Global Innovation Technologist Awards, which recognize scientific and technological advancements with measurable academic and practical significance. Contributions spanning metabolic engineering, CRISPR research, supramolecular chemistry, and open-source automation technologies demonstrate consistent engagement with innovation-oriented scientific inquiry.[1]

The combination of peer-reviewed publications, measurable citation performance, and interdisciplinary technical expertise supports recognition within the field of biology and life sciences. Li’s work illustrates the integration of engineering design principles with biological and chemical sciences to address contemporary research challenges.[4]

Conclusion

The scholarly profile of Shuai Li reflects interdisciplinary scientific engagement across synthetic biology, supramolecular chemistry, and laboratory engineering technologies. Through publications in recognized journals and contributions to biological automation systems, Li has participated in research initiatives with relevance to modern biotechnology and life sciences. The body of work demonstrates methodological diversity, collaborative scientific activity, and continuing participation in innovation-oriented academic research.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Shuai Li, Author ID 60597499200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60597499200
  2. Li, S. et al. (2021). BioSamplr: An open source, low cost automated sampling system for bioreactors. HardwareX.
    https://doi.org/10.1016/j.ohx.2021.e00177
  3. Li, S. et al. (2021). Dynamic control over feedback regulatory mechanisms improves NADPH flux and xylitol biosynthesis in engineered E. coli. Metabolic Engineering.
    https://doi.org/10.1016/j.ymben.2021.01.005
  4. ORCID. (n.d.). Shuai Li ORCID profile and educational background.
    https://orcid.org/0000-0002-1537-3956
  5. Crossref Metadata Search. (n.d.). Publication metadata associated with Shuai Li.
  6. Li, S. et al. (2020). Escherichia coli Cas1/2 Endonuclease Complex Modifies Self-Targeting CRISPR/Cascade Spacers Reducing Silencing Guide Stability. ACS Synthetic Biology.
    https://doi.org/10.1021/acssynbio.0c00398
  7. Li, S. et al. (2020). Supramolecular chiroptical switches. Chemical Society Reviews.
    https://doi.org/10.1039/d0cs00191k
  8. Li, S. et al. (2017). Alanine-Based Chiral Metallogels via Supramolecular Coordination Complex Platforms: Metallogelation Induced Chirality Transfer. Journal of the American Chemical Society.
    https://doi.org/10.1021/jacs.7b10769

Mutinda Cleophas Kyama | Medicine and Health Sciences | Research Excellence Award

Published on by Innovation Technologist

Research Excellence Award

Cleophas Mutinda Kyama
Jomo Kenyatta University of Agriculture and Technology, Kenya
Cleophas Mutinda Kyama
Affiliation Jomo Kenyatta University of Agriculture and Technology
Country Kenya
Scopus ID 57216717397
Documents 65
Citations 2,698
h-index 29
Subject Area Medicine and Health Sciences
Event Global Innovation Technologist Awards
ORCID 0000-0001-6459-1514

Cleophas Mutinda Kyama is a Kenyan biomedical scientist, clinical cytologist, and academic researcher associated with the Jomo Kenyatta University of Agriculture and Technology (JKUAT). His scholarly contributions span cancer biology, molecular diagnostics, parasitology, toxicology, infectious disease detection, and translational biomedical sciences. His publication record demonstrates sustained engagement in interdisciplinary health science research with applications in oncology, infectious diseases, immunology, and molecular medicine.[1] The researcher has received significant scholarly attention through citations and collaborative biomedical investigations, particularly in cervical cancer diagnostics, phytomedicine, CRISPR-based diagnostic technologies, and antivenom development.[2]

Abstract

The Research Excellence Award recognition article documents the scholarly achievements and biomedical research contributions of Cleophas Mutinda Kyama. His scientific portfolio encompasses molecular diagnostics, oncology, pharmacological investigations, parasitology, immunological research, and translational health sciences. Through peer-reviewed publications, collaborative international research, and laboratory-based innovations, Kyama has contributed to the advancement of diagnostic technologies and therapeutic investigations relevant to public health challenges in Africa and globally.[3] The researcher’s work demonstrates integration of computational biology, molecular docking, in vitro experimentation, and nanotechnology-assisted diagnostics, reflecting contemporary interdisciplinary scientific approaches.[4]

Keywords

Biomedical Sciences; Molecular Diagnostics; Cervical Cancer Research; CRISPR-Cas12a; Oncology; Cytology; Antivenom Research; Pharmacology; Translational Medicine; Public Health Research; Cancer Therapeutics; Computational Biology.

Introduction

Biomedical and translational health sciences have increasingly relied upon interdisciplinary approaches integrating molecular biology, computational modeling, immunology, and experimental medicine. Within this scientific landscape, Cleophas Mutinda Kyama has contributed to research efforts addressing infectious diseases, cancer diagnostics, toxicology, and therapeutic screening technologies.[5] His work has emphasized practical healthcare applications, particularly within African biomedical contexts where diagnostic accessibility and disease management remain major public health priorities.

Kyama’s research trajectory demonstrates sustained engagement in clinically relevant investigations involving HPV-associated cervical cancer screening, SARS-CoV-2 detection systems, phytochemical anticancer studies, and venom toxicology. Several of his investigations combine computational methodologies with laboratory validation, contributing to evidence-based biomedical innovation and translational healthcare research.[6]

Research Profile

Cleophas Mutinda Kyama served at Jomo Kenyatta University of Agriculture and Technology as a Biomedical Scientist and Senior Lecturer in Medical Laboratory Sciences. His academic and professional work has focused on laboratory diagnostics, cytology, cancer biology, molecular therapeutics, and pathogen detection technologies.[1]

The researcher’s Scopus profile reports 65 scholarly documents with 2,698 citations and an h-index of 29, reflecting measurable scientific visibility and sustained citation impact across biomedical disciplines.[1] His work has appeared in journals including PLOS ONE, BMC Complementary Medicine and Therapies, Diagnostics, Toxicon: X, Toxins, and the South African Journal of Botany.

  • Research specialization in molecular diagnostics and biomedical laboratory sciences.
  • Interdisciplinary research combining computational biology and experimental medicine.
  • Published investigations involving oncology, toxicology, parasitology, and virology.
  • Contributions to public health-oriented biomedical innovation.

Research Contributions

Among Kyama’s notable scientific contributions are investigations into cervical cancer therapeutics and molecular screening technologies. His 2025 study in PLOS ONE explored the molecular mechanisms of Solanecio mannii aqueous root extracts against cervical cancer using computational and experimental validation methodologies.[2]

Additional research explored network pharmacology and molecular docking strategies for prostate cancer treatment investigations using Aspilia pluriseta. These studies integrated in vitro analysis with computational biology techniques to evaluate antiproliferative activity and potential therapeutic mechanisms.[3]

Kyama also contributed to advanced infectious disease diagnostics through CRISPR-Cas12a and hybridization chain reaction methodologies for SARS-CoV-2 detection. This work reflected the growing importance of rapid molecular diagnostic systems during global public health emergencies.[4]

In toxicological and immunological sciences, his studies investigated venom lethality, monoclonal antibody development, and antivenom efficacy involving Naja ashei toxins. These investigations contributed to understanding envenomation management and toxin-neutralizing biomedical strategies.[7]

Publications

Selected publications associated with Cleophas Mutinda Kyama include peer-reviewed journal articles, preprints, and translational biomedical studies relevant to oncology, diagnostics, toxicology, and parasitology.

  1. Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE (2025).
  2. Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies (2024).
  3. Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics (2023).
  4. Evaluation of lethality and cytotoxic effects induced by Naja ashei venom and efficacy of selected antivenoms in Kenya. Toxicon: X (2022).
  5. Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins (2022).

Research Impact

The scientific impact of Cleophas Mutinda Kyama’s work is reflected through citation metrics, interdisciplinary collaborations, and practical biomedical applications. His investigations into molecular diagnostics and therapeutic evaluation contribute to contemporary discussions surrounding affordable healthcare technologies, precision diagnostics, and evidence-based medicinal research.[4]

Research involving CRISPR-based diagnostics and nanoparticle-assisted detection systems demonstrates alignment with emerging biomedical technologies that support rapid pathogen identification and translational healthcare innovation.[8] Similarly, his toxicological and antivenom studies address healthcare concerns related to snakebite management in endemic regions.

The integration of phytomedicine, computational molecular analysis, and laboratory validation techniques further reflects a multidisciplinary scientific framework capable of supporting future biomedical innovation and collaborative translational research initiatives.[3]

Award Suitability

The scholarly profile of Cleophas Mutinda Kyama demonstrates characteristics associated with international academic recognition and research excellence awards. His documented publication history, citation impact, interdisciplinary biomedical investigations, and sustained engagement in translational health sciences collectively support recognition within the framework of the Global Innovation Technologist Awards.[1]

  • Demonstrated publication productivity in indexed scientific journals.
  • Strong citation impact and measurable academic influence.
  • Contributions to molecular diagnostics and translational medicine.
  • Interdisciplinary biomedical innovation relevant to public health.
  • Research engagement involving computational and experimental methodologies.

Conclusion

Cleophas Mutinda Kyama has established a research profile characterized by interdisciplinary biomedical inquiry, molecular diagnostic innovation, and translational scientific investigations addressing major health challenges. His academic contributions in oncology, toxicology, molecular biology, and infectious disease diagnostics demonstrate sustained scholarly engagement and measurable scientific impact.[5] Through collaborative biomedical research and publication activity, his work contributes to evolving scientific understanding within medicine and health sciences while supporting broader healthcare research objectives relevant to emerging global health priorities.

References

  1. Elsevier. (n.d.). Scopus author details: Cleophas Mutinda Kyama, Author ID 57216717397. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57216717397
  2. Kyama, C. M. et al. (2025). Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE.
    https://doi.org/10.1371/journal.pone.0323680
  3. Kyama, C. M. et al. (2024). Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies.
    https://doi.org/10.1186/s12906-024-04642-8
  4. Kyama, C. M. et al. (2023). Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics.
    https://doi.org/10.3390/diagnostics13091644
  5. Jomo Kenyatta University of Agriculture and Technology. (n.d.). Medical Laboratory Sciences and Biomedical Research Activities.
  6. Kyama, C. M. et al. (2022). Expression of the Fab enzymes from Plasmodium falciparum after exposure to Artemisia afra plant extracts. Journal of Parasitic Diseases.
    https://doi.org/10.1007/s12639-022-01537-8
  7. Kyama, C. M. et al. (2022). Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins.
    https://doi.org/10.3390/toxins14040285
  8. Kyama, C. M. et al. (2020). Development of HPV 16/18 E6 oncoprotein paper-based nanokit for enhanced cervical cancer screening.
    https://doi.org/10.1101/2020.04.29.20084459

Zhanyang Qian | Neuroscience | Research Excellence Award

Published on by Innovation Technologist

Dr. Zhanyang Qian | Neuroscience | Research Excellence Award

Nantong University | China

Dr. Zhanyang Qian is a neural regeneration scientist specializing in innovative therapeutic strategies for spinal cord injury, with a strong focus on immunomodulation, neuroinflammation, and cellular repair mechanisms. His research integrates advanced molecular immunology, mitochondrial biology, and translational animal models to uncover pathways that drive neural protection and functional recovery. He has secured multiple national-level grants and prestigious provincial talent recognitions, reflecting his rapidly rising impact in the field. Dr. Qian has authored a robust portfolio of high-impact publications, including several first- and corresponding-author papers in top-tier journals, with his work cited by leading neuroscience outlets. His studies have advanced understanding of microglial and astrocytic responses, efferocytosis in senescent macrophages, and mitophagy-driven neuroprotection, contributing valuable insights to the development of targeted interventions for central nervous system injury. Beyond research, he contributes to the scientific community as a committee member in neurological regeneration, serves on an editorial board, and reviews for reputable journals. Dr. Qian is recognized for his leadership in pioneering mechanistic discoveries and translating them toward clinically relevant therapeutic strategies, positioning him as an emerging expert in spinal cord injury repair and neural regeneration.

Profiles: Scopus | Orcid

Featured Publications

Xia, M., Li, C., Zhang, Y., Wang, T., Zhang, C., Zhou, J., Zhu, X., Hong, H., Li, H., Qian, Z., et al. (2025). GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair. Redox Biology, 103857.

Xia, M., Li, C., Chen, J., Wu, C., Zhang, J., Hong, H., Jiang, J., Xu, G., Qian, Z., & Cui, Z. (2025). Activation of FANCC attenuates mitochondrial ROS-driven necroptosis by targeting TBK1-dependent mitophagy in astrocytes after spinal cord injury. Theranostics.

Qian, Z., Li, R., Zhao, T., Xie, K., Li, P., Li, G., Shen, N., Gong, J., Hong, X., & Yang, L., et al. (2024). Blockade of the ADAM8–Fra-1 complex attenuates neuroinflammation by suppressing the Map3k4/MAPKs axis after spinal cord injury. Cellular & Molecular Biology Letters, 29, Article 589.

Qian, Z., Xia, M., Zhao, T., Li, Y., Li, G., Zhang, Y., Li, H., & Yang, L. (2024). ACOD1, rather than itaconate, facilitates p62-mediated activation of Nrf2 in microglia post spinal cord contusion. Clinical and Translational Medicine, 14, Article e1661.

Chang, J., Qian, Z., Wang, B., Cao, J., Zhang, S., Jiang, F., Kong, R., Yu, X., Cao, X., & Yang, L., et al. (2023). Transplantation of A2 type astrocytes promotes neural repair and remyelination after spinal cord injury. Cell Communication and Signaling, 21(1).